Abstract:Background: Recent findings suggest that the plasma axonal structural protein, neurofilament light (NFL) chain, may serve as a potential blood biomarker for early signs of neurodegenerative diseases, such as Alzheimer's disease (AD). Given the need for early detection of neurodegenerative disorders, the current study investigated the associations between regional cerebral blood flow (rCBF) in brain regions associated with neurodegenerative disorders and memory function with plasma NFL in AD, mild cognitive impairment (MCI), and healthy controls (HCs). Methods: We recruited 29 AD, 76 MCI, and 39 HCs from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database in the current cross-sectional study. We used Pearson's correlation models adjusted for the effect of age, sex, and APOE genotype to investigate the association between plasma NFL and rCBF. Results: We found non-significant differences in age (F(2, 141) = 1.304; P = 0.275) and years of education (F(2, 141) = 0.013; P = 0.987). Additionally, we found significant differences between groups in terms of MMSE scores (F(2, 141) = 100.953; P < 0.001). Despite the observation of significantly reduced rCBF in AD and MCI groups versus HCs, we did not detect significant differences in plasma NFL between these groups. We found significant negative associations between plasma NFL and rCBF in various AD-related regions, these findings were only observed after analyses in all participants, and were observed in HCs alone and no significant associations were observed in the AD or MCI groups. Conclusion: These outcomes add to our current understanding surrounding the use of rCBF and plasma NFL biomarkers as tools for early detection and diagnosis of neurodegenerative diseases. A conclusion might be that the association between NFL and impaired rCBF exists before the clinical symptoms appear. Further longitudinal studies with a large sample size should be performed to examine the correlation between plasma NFL and rCBF in order to understand these complex relationships.

Levels of plasma neurofilament light chain and cognitive function in patients with Alzheimer or Parkinson disease

Diagnostic Value of Isolated Plasma Biomarkers and Its Combination in Neurodegenerative Dementias: A Multicenter Cohort Study

Plasma Neurofilament Light Chain Levels in Alzheimer’s Disease

P3-435: plasma neurofilament light as a measure of neurodegeneration for nondemented individuals

Plasma Neurofilament Light As a Longitudinal Biomarker of Neurodegeneration in Alzheimer’s Disease

Plasma neurofilament light chain associated with impaired regional cerebral blood flow in healthy individuals

Neurofilament Light Chain Plasma Concentration Predicts Neurodegeneration and Clinical Progression in Nondemented Elderly Adults

Evaluation of plasma levels of NFL, GFAP, UCHL1 and tau as Parkinson's disease biomarkers using multiplexed single molecule counting

Plasma NFL Disrupt Cognitive Integrity Via Coupling the Interactions of Core Subsystem and Frontoparietal Network in Alzheimer's Disease

Relationship Between Plasma NFL and Disease Progression in Parkinson’s Disease: a Prospective Cohort Study

Serum NFL levels predict progression of motor impairment and reduction in putamen dopamine transporter binding ratios in de novo Parkinson's disease: An 8-year longitudinal study.

Relationship between plasma NFL and disease progression in Parkinson's disease: a prospective cohort study

Neurofilament Light Chain in Cerebrospinal Fluid and Blood As a Biomarker for Neurodegenerative Diseases: A Systematic Review and Meta-Analysis.

Peripheral Neurofilament Light (NFL) Chain Level Predicts the Two‐year Outcome of Amnestic Mild Cognitive Impairment in Chinese Han Population

Plasma Neurofilament Light and Longitudinal Progression of White Matter Hyperintensity in Elderly Persons Without Dementia.

Genome-wide Association Study Identifies Two Loci Influencing Plasma Neurofilament Light Levels

Plasma neurofilament light chain as a biomarker of Alzheimer’s disease in Subjective Cognitive Decline and Mild Cognitive Impairment

Neurofilament Light Chain As a Potential Biomarker in Plasma for Alzheimer's Disease and Mild Cognitive Impairment: A Systematic Review and a Meta-Analysis.

Inflammation Affects Dynamic Functional Network Connectivity Pattern Changes Via Plasma NFL in Cognitive Impairment Patients.

Association between plasma neurofilament light chain levels and cognitive function in patients with Parkinson's disease

Blood Neurofilament Levels Predict Cognitive Decline across the Alzheimer's Disease Continuum